Trial NCT04533399; PACTR202009726132275
Publication Shinde V, N Engl J Med, 2021
Primary outcome on the report: 1) Occurrence of unsolicited adverse events (medically attended, serious, and those of special interest through Day 35; 2) solicited local and systemic adverse events evaluated via reactogenicity diary for 7 days following each vaccination; 3) confirmed symptomatic mild, moderate, or severe Covid-19 in participants seronegative to SARS-CoV-2 at baseline occurring 7 days after receipt of the second study vaccine (ie, after Day 28)

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.